Analysts expect Ardelyx to report a Q2 2026 loss of $0.05 per share on revenue of $108.42 million, while the current stock price of $9.15 remains significantly below the $12.50 average analyst price target. The primary focus for investors this quarter is the net sales performance of IBSRELA, which is considered the leading indicator for the company's trajectory toward sustainable profitability.
Markets are also closely monitoring the adoption rate of XPHOZAH within the hyperphosphatemia market following its expanded commercial rollout. Sustained growth in prescription volumes and nephrologist engagement are viewed as essential catalysts for a potential valuation rerating in the second half of the year.